{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:16:30Z","timestamp":1790741790233,"version":"4.1.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","award":["2020\/985800-0"],"award-info":[{"award-number":["2020\/985800-0"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-001754"],"award-info":[{"award-number":["INV-001754"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-001754"],"award-info":[{"award-number":["INV-001754"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1084276"],"award-info":[{"award-number":["OPP1084276"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1135288"],"award-info":[{"award-number":["OPP1135288"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Centennial Scholarship Fund"},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N013638\/1"],"award-info":[{"award-number":["MR\/N013638\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["CCF17-7779"],"award-info":[{"award-number":["CCF17-7779"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["218261\/Z\/19\/Z"],"award-info":[{"award-number":["218261\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI147321-01"],"award-info":[{"award-number":["1R01AI147321-01"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA208D-2505B"],"award-info":[{"award-number":["RIA208D-2505B"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UK Research & Innovation Economic and Social Research Council","award":["ES\/P008011\/1"],"award-info":[{"award-number":["ES\/P008011\/1"]}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis (TB) is preventable and curable but eliminating it has proven challenging. Safe and effective TB vaccines that can rapidly reduce disease burden are essential for achieving TB elimination. We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>We developed a system of epidemiological and economic models, calibrated to demographic, epidemiological, and health service data in 105 LMICs. For each country, we assessed the likely future course of TB-related outcomes under several vaccine introduction scenarios, compared to a \u201cno-new-vaccine\u201d counterfactual. Vaccine scenarios considered 2 vaccine product profiles (1 targeted at infants, 1 at adolescents\/adults), both assumed to prevent progression to active TB. Key economic inputs were derived from the Global Health Cost Consortium, World Health Organization (WHO) patient cost surveys, and the published literature. We estimated the incremental impact of vaccine introduction for a range of health and economic outcomes. In the base-case, we assumed a vaccine price of $4.60 and used a 1\u00d7 per-capita gross domestic product (GDP) cost-effectiveness threshold (both varied in sensitivity analyses). Vaccine introduction was estimated to require substantial near-term resources, offset by future cost-savings from averted TB burden. From a health system perspective, adolescent\/adult vaccination was cost-effective in 64 of 105 LMICs. From a societal perspective (including productivity gains and averted patient costs), adolescent\/adult vaccination was projected to be cost-effective in 73 of 105 LMICs and cost-saving in 58 of 105 LMICs, including 96% of countries with higher TB burden. When considering the monetized value of health gains, we estimated that introduction of an adolescent\/adult vaccine could produce $283 to 474 billion in economic benefits by 2050. Limited data availability required assumptions and extrapolations that may omit important country-level heterogeneity in epidemiology and costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TB vaccination would be highly impactful and cost-effective in most LMICs. Further efforts are needed for future development, adoption, and implementation of novel TB vaccines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004155","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T13:33:02Z","timestamp":1674567182000},"page":"e1004155","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":42,"title":["The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8467-1324","authenticated-orcid":true,"given":"Allison","family":"Portnoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8923-0301","authenticated-orcid":true,"given":"Rebecca A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9291-1511","authenticated-orcid":true,"given":"Matthew","family":"Quaife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7364-1026","authenticated-orcid":true,"given":"Chathika K.","family":"Weerasuriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4191-0361","authenticated-orcid":true,"given":"Christinah","family":"Mukandavire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-0944","authenticated-orcid":true,"given":"Roel","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arminder K.","family":"Deol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7457-386X","authenticated-orcid":true,"given":"Shelly","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebiat","family":"Gebreselassie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Zignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Yoon","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond C. W.","family":"Hutubessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s Garcia","family":"Baena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0962-8868","authenticated-orcid":true,"given":"Nobuyuki","family":"Nishikiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-8255","authenticated-orcid":true,"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4410-6635","authenticated-orcid":true,"given":"Richard G.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-016X","authenticated-orcid":true,"given":"Nicolas A.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"pmed.1004155.ref001","unstructured":"World Health Organization. Global Tuberculosis Report 2021. Geneva: World Health Organization. 14 October 2021. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2021 (accessed 1 December 2021)."},{"key":"pmed.1004155.ref002","volume-title":"The End TB Strategy","author":"World Health Organization","year":"2015"},{"issue":"10","key":"pmed.1004155.ref003","doi-asserted-by":"crossref","first-page":"e1372","DOI":"10.1016\/S2214-109X(21)00299-0","article-title":"Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis","volume":"9","author":"S Silva","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"25","key":"pmed.1004155.ref004","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final Analysis of a Trial of M72\/AS01(E) Vaccine to Prevent Tuberculosis","volume":"381","author":"DR Tait","year":"2019","journal-title":"N Engl J Med"},{"key":"pmed.1004155.ref005","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.3841999","article-title":"The Full Value of Vaccine Assessments (FVVA): A Framework to Assess and Communicate the Value of Vaccines for Investment and Introduction Decision Making","author":"R Hutubessy","year":"2021"},{"issue":"3","key":"pmed.1004155.ref006","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02414-2019","article-title":"The case for assessing the full value of new tuberculosis vaccines","volume":"55","author":"N Gebreselassie","year":"2020","journal-title":"Eur Respir J"},{"key":"pmed.1004155.ref007","article-title":"The impact of alternative delivery strategies for novel tuberculosis vaccines in low- and middle-income countries: a modelling study","author":"RA Clark","year":"2022","journal-title":"medRxiv"},{"key":"pmed.1004155.ref008","volume-title":"World Bank Country and Lending Groups","author":"World Bank","year":"2021"},{"key":"pmed.1004155.ref009","unstructured":"World Health Organization. WHO releases new global lists of high-burden countries for TB, HIV-associated TB and drug-resistant TB. 17 June 2021. Available from: https:\/\/www.who.int\/news\/item\/17-06-2021-who-releases-new-global-lists-of-high-burden-countries-for-tb-hiv-associated-tb-and-drug-resistant-tb (accessed 1 July 2021)."},{"key":"pmed.1004155.ref010","volume-title":"WHO Preferred Product Characteristics for New Tuberculosis Vaccines","author":"World Health Organization","year":"2018"},{"key":"pmed.1004155.ref011","volume-title":"WHO-UNICEF estimates of DTP3 coverage: monitoring system 2019 global summary","author":"World Health Organization","year":"2020"},{"issue":"564","key":"pmed.1004155.ref012","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax4607","article-title":"Potential impact of tuberculosis vaccines in China, South Africa, and India","volume":"12","author":"RC Harris","year":"2020","journal-title":"Sci Transl Med"},{"key":"pmed.1004155.ref013","author":"World Health Organization","year":"2021"},{"issue":"11","key":"pmed.1004155.ref014","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","article-title":"Disability weights for the Global Burden of Disease 2013 study","volume":"3","author":"JA Salomon","year":"2015","journal-title":"Lancet Glob Health"},{"key":"pmed.1004155.ref015","volume-title":"Global Burden of Disease Study 2019 (GBD 2019) Reference Life Table","author":"Global Burden of Disease Collaborative Network","year":"2021"},{"issue":"9","key":"pmed.1004155.ref016","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40273-015-0279-6","article-title":"Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review","volume":"33","author":"YV Laurence","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"pmed.1004155.ref017","doi-asserted-by":"crossref","first-page":"802","DOI":"10.5588\/ijtld.19.0694","article-title":"Cost of tuberculosis treatment in low- and middle-income countries: systematic review and meta-regression","volume":"24","author":"M Siapka","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"pmed.1004155.ref018","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s12879-016-1802-x","article-title":"The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan","volume":"16","author":"S van den Hof","year":"2016","journal-title":"BMC Infect Dis"},{"key":"pmed.1004155.ref019","unstructured":"Global Health Cost Consortium. Unit Cost Study Repository, Version 5.0. 8 May 2020. Available from: https:\/\/ghcosting.org\/pages\/data\/ucsr\/app\/ (accessed 3 February 2021)."},{"key":"pmed.1004155.ref020","volume-title":"Tuberculosis patient cost surveys: a hand book","author":"World Health Organization","year":"2017"},{"key":"pmed.1004155.ref021","first-page":"2015","volume-title":"National surveys of costs faced by TB patients and their households","author":"World Health Organization","year":"2022"},{"key":"pmed.1004155.ref022","author":"A Portnoy","journal-title":"The patient costs of TB treatment in low- and middle-income countries: a meta-regression analysis of 20 nationally-representative patient cost surveys"},{"key":"pmed.1004155.ref023","unstructured":"International Monetary Fund. World Economic Outlook Database, October 2021. Last updated: 1 July 2021. [Online] Accessed 12 April 2022. Available from: https:\/\/www.imf.org\/en\/Publications\/WEO\/weo-database\/2021\/October."},{"key":"pmed.1004155.ref024","volume-title":"World development indicators","author":"World Bank","year":"2020"},{"key":"pmed.1004155.ref025","unstructured":"UNICEF. Vaccines pricing data. 8 March 2022. Available from: https:\/\/www.unicef.org\/supply\/vaccines-pricing-data (accessed 17 March 2022)."},{"key":"pmed.1004155.ref026","unstructured":"UNICEF. Costs of Vaccinating a Child. 14 August 2020. Available from: https:\/\/immunizationeconomics.org\/recent-activity\/2021\/6\/15\/standard-costs-of-vaccinating-a-child (accessed 20 January 2021)."},{"issue":"9","key":"pmed.1004155.ref027","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40273-020-00930-6","article-title":"Producing Standardized Country-Level Immunization Delivery Unit Cost Estimates","volume":"38","author":"A Portnoy","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"pmed.1004155.ref028","volume-title":"GAVI Alliance Vaccine Introduction Grant and Operational Support for Campaigns Policy. Version No. 1.0","author":"Gavi The Vaccine Alliance","year":"2013"},{"key":"pmed.1004155.ref029","author":"World Bank","year":"2021"},{"issue":"6","key":"pmed.1004155.ref030","doi-asserted-by":"crossref","first-page":"e000964","DOI":"10.1136\/bmjgh-2018-000964","article-title":"Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data","volume":"3","author":"J Ochalek","year":"2018","journal-title":"BMJ Glob Health"},{"issue":"8","key":"pmed.1004155.ref031","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","article-title":"Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research","volume":"19","author":"B Woods","year":"2016","journal-title":"Value Health"},{"issue":"2","key":"pmed.1004155.ref032","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.clinthera.2022.01.011","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations","volume":"44","author":"D Husereau","year":"2022","journal-title":"Clin Ther"},{"issue":"6","key":"pmed.1004155.ref033","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","article-title":"Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20146","volume":"15","author":"AH Briggs","year":"2012","journal-title":"Value Health"},{"issue":"28","key":"pmed.1004155.ref034","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1016\/j.vaccine.2022.05.042","article-title":"Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis","volume":"40","author":"MM Janko","year":"2022","journal-title":"Vaccine"},{"issue":"12","key":"pmed.1004155.ref035","doi-asserted-by":"crossref","first-page":"e0260808","DOI":"10.1371\/journal.pone.0260808","article-title":"Cost-effectiveness of HPV vaccination in 195 countries: A meta-regression analysis","volume":"16","author":"KL Rosettie","year":"2021","journal-title":"PLoS ONE"},{"issue":"2","key":"pmed.1004155.ref036","article-title":"Economic Impact of Introducing the RTS,S Malaria Vaccine: Cost-Effectiveness and Budget Impact Analysis in 41 Countries.","volume":"4","author":"C Sauboin","year":"2019","journal-title":"MDM Policy Pract"},{"issue":"2","key":"pmed.1004155.ref037","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/heapol\/czx166","article-title":"Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia","volume":"33","author":"T Loganathan","year":"2018","journal-title":"Health Policy Plan"},{"issue":"5","key":"pmed.1004155.ref038","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","article-title":"Cost-Effectiveness Thresholds: the Past, the Present and the Future","volume":"36","author":"P Thokala","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"pmed.1004155.ref039","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jval.2020.07.012","article-title":"Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006\u20132018","volume":"24","author":"M. Jit","year":"2021","journal-title":"Value Health"},{"issue":"43","key":"pmed.1004155.ref040","doi-asserted-by":"crossref","first-page":"15520","DOI":"10.1073\/pnas.1404386111","article-title":"Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries","volume":"111","author":"GM Knight","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pmed.1004155.ref041","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41467-020-20731-x","article-title":"Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine","volume":"12","author":"H Fu","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"pmed.1004155.ref042","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12916-021-01932-7","article-title":"The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China","volume":"19","author":"CK Weerasuriya","year":"2021","journal-title":"BMC Med"},{"issue":"11","key":"pmed.1004155.ref043","first-page":"984","article-title":"Modeling the economic benefits of better TB vaccines","volume":"5","author":"DM Bishai","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"pmed.1004155.ref044","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S1473-3099(22)00222-5","article-title":"Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial","volume":"22","author":"MF Cotton","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"pmed.1004155.ref045","unstructured":"The Global Fund. Fight for What Counts: The Global Fund Investment Case. Seventh Replenishment 2022. 23 February 2022. Available from: https:\/\/www.theglobalfund.org\/en\/fight-for-what-counts\/ (accessed 16 March 2022)."}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T13:33:45Z","timestamp":1674567225000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004155"}},"subtitle":[],"editor":[{"given":"Megan B.","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004155","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.05.04.22274654","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]}}}